Chlorpropamide
A first-generation sulfonylurea oral antidiabetic drug that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. It has an unusually long half-life that allows once-daily dosing but also increases the risk of prolonged hypoglycemia. It has largely been replaced by second-generation sulfonylureas and newer drug classes due to its side effect profile.
Molekularmasse
276,7400 g/mol
LogP
2,30
TPSA
83,70 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
InChI
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
Molecular Formula
C10H13ClN2O3S
HBD / HBA
2 / 3
Rotierbare Bindungen
4
Schwere Atome
17
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A first-generation sulfonylurea oral antidiabetic drug that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. It has an unusually long half-life that allows once-daily dosing but also increases the risk of prolonged hypoglycemia. It has largely been replaced by second-generation sulfonylureas and newer drug classes due to its side effect profile.
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Yes, Chlorpropamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL498. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2727. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="chlorpropamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/chlorpropamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/chlorpropamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/chlorpropamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="chlorpropamide"></drugfyi-drug>